Literature DB >> 32667833

MR texture analysis in differentiating renal cell carcinoma from lipid-poor angiomyolipoma and oncocytoma.

Abdul Razik1, Ankur Goyal1, Raju Sharma1, Devasenathipathy Kandasamy1, Amlesh Seth2, Prasenjit Das3, Balaji Ganeshan4.   

Abstract

OBJECTIVES: To assess the utility of magnetic resonance texture analysis (MRTA) in differentiating renal cell carcinoma (RCC) from lipid-poor angiomyolipoma (lpAML) and oncocytoma.
METHODS: After ethical approval, 42 patients with 54 masses (34 RCC, 14 lpAML and six oncocytomas) who underwent MRI on a 1.5 T scanner (Avanto, Siemens, Erlangen, Germany) between January 2011 and December 2012 were retrospectively included in the study. MRTA was performed on the TexRAD research software (Feedback Plc., Cambridge, UK) using free-hand polygonal region of interest (ROI) drawn on the maximum cross-sectional area of the tumor to generate six first-order statistical parameters. The Mann-Whitney U test was used to look for any statically significant difference. The receiver operating characteristic (ROC) curve analysis was done to select the parameter with the highest class separation capacity [area under the curve (AUC)] for each MRI sequence.
RESULTS: Several texture parameters on MRI showed high-class separation capacity (AUC > 0.8) in differentiating RCC from lpAML and oncocytoma. The best performing parameter in differentiating RCC from lpAML was mean of positive pixels (MPP) at SSF 2 (AUC: 0.891) on DWI b500. In differentiating RCC from oncocytoma, the best parameter was mean at SSF 0 (AUC: 0.935) on DWI b1000.
CONCLUSIONS: MRTA could potentially serve as a useful non-invasive tool for differentiating RCC from lpAML and oncocytoma. ADVANCES IN KNOWLEDGE: There is limited literature addressing the role of MRTA in differentiating RCC from lpAML and oncocytoma. Our study demonstrated several texture parameters which were useful in this regard.

Entities:  

Mesh:

Year:  2020        PMID: 32667833      PMCID: PMC7548360          DOI: 10.1259/bjr.20200569

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  39 in total

1.  The value of quantitative CT texture analysis in differentiation of angiomyolipoma without visible fat from clear cell renal cell carcinoma on four-phase contrast-enhanced CT images.

Authors:  M-W You; N Kim; H J Choi
Journal:  Clin Radiol       Date:  2019-04-20       Impact factor: 2.350

2.  Texture analysis as a radiomic marker for differentiating renal tumors.

Authors:  HeiShun Yu; Jonathan Scalera; Maria Khalid; Anne-Sophie Touret; Nicolas Bloch; Baojun Li; Muhammad M Qureshi; Jorge A Soto; Stephan W Anderson
Journal:  Abdom Radiol (NY)       Date:  2017-10

3.  Machine learning-based quantitative texture analysis of CT images of small renal masses: Differentiation of angiomyolipoma without visible fat from renal cell carcinoma.

Authors:  Zhichao Feng; Pengfei Rong; Peng Cao; Qingyu Zhou; Wenwei Zhu; Zhimin Yan; Qianyun Liu; Wei Wang
Journal:  Eur Radiol       Date:  2017-11-13       Impact factor: 5.315

4.  Differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma in contrast-enhanced MDCT images using quantitative feature classification.

Authors:  Han Sang Lee; Helen Hong; Dae Chul Jung; Seunghyun Park; Junmo Kim
Journal:  Med Phys       Date:  2017-06-09       Impact factor: 4.071

Review 5.  Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat.

Authors:  Byung Kwan Park
Journal:  AJR Am J Roentgenol       Date:  2017-07-20       Impact factor: 3.959

6.  Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.

Authors:  Jonathan R Young; Daniel Margolis; Steven Sauk; Allan J Pantuck; James Sayre; Steven S Raman
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

7.  Usefulness of CT texture analysis in differentiating benign and malignant renal tumours.

Authors:  Y Deng; E Soule; E Cui; A Samuel; S Shah; C Lall; C Sundaram; K Sandrasegaran
Journal:  Clin Radiol       Date:  2019-10-24       Impact factor: 2.350

8.  Comparison of Biexponential and Monoexponential Model of Diffusion-Weighted Imaging for Distinguishing between Common Renal Cell Carcinoma and Fat Poor Angiomyolipoma.

Authors:  Yuqin Ding; Mengsu Zeng; Shengxiang Rao; Caizhong Chen; Caixia Fu; Jianjun Zhou
Journal:  Korean J Radiol       Date:  2016-10-31       Impact factor: 3.500

9.  Contrast-Enhanced CT Texture Analysis for Distinguishing Fat-Poor Renal Angiomyolipoma From Chromophobe Renal Cell Carcinoma.

Authors:  Guangjie Yang; Aidi Gong; Pei Nie; Lei Yan; Wenjie Miao; Yujun Zhao; Jie Wu; Jingjing Cui; Yan Jia; Zhenguang Wang
Journal:  Mol Imaging       Date:  2019 Jan-Dec       Impact factor: 4.488

10.  Value of radiomics in differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma.

Authors:  Yajuan Li; Xialing Huang; Yuwei Xia; Liling Long
Journal:  Abdom Radiol (NY)       Date:  2020-10
View more
  4 in total

1.  A CT-based radiomics nomogram for differentiation of renal oncocytoma and chromophobe renal cell carcinoma with a central scar-matched study.

Authors:  Xiaoli Li; Qianli Ma; Pei Nie; Yingmei Zheng; Cheng Dong; Wenjian Xu
Journal:  Br J Radiol       Date:  2021-11-04       Impact factor: 3.039

2.  The role of MRI-based texture analysis to predict the severity of brain injury in neonates with perinatal asphyxia.

Authors:  Fatma Ceren Sarioglu; Orkun Sarioglu; Handan Guleryuz; Burak Deliloglu; Funda Tuzun; Nuray Duman; Hasan Ozkan
Journal:  Br J Radiol       Date:  2022-01-27       Impact factor: 3.629

Review 3.  Radiomics to better characterize small renal masses.

Authors:  Teele Kuusk; Joana B Neves; Maxine Tran; Axel Bex
Journal:  World J Urol       Date:  2021-01-26       Impact factor: 4.226

Review 4.  Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.

Authors:  Francesco Trevisani; Matteo Floris; Roberto Minnei; Alessandra Cinque
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.